Amylon Therapeutics B.V.
https://amylon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amylon Therapeutics B.V.
30 Rising Leaders In The Life Sciences
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut.
Biopharma Quarterly Dealmaking Statistics, Q3 2017
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Venture Funding Deals: Spin-Offs Gain Their Own Footing
Pfizer-backed SpringWorks, ProQR spin-out Amylon and Landos, the first firm out of accelerator Xontogeny, gain their own financing. Other venture rounds support Autolus, Grid Therapeutics, Excision and more.
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- ProQR